Mounjaro vs. Zepbound 2026: Same Tirzepatide, Different Indications
Mounjaro and Zepbound are the exact same molecule — tirzepatide — from the exact same manufacturer (Eli Lilly). The dose ranges are identical (2.5 to 15 mg weekly). The pen designs are identical. The side effect profile is identical. The only meaningful difference is the FDA-approved label: Mounjaro is approved for Type 2 diabetes (May 2022); Zepbound is approved for chronic weight management (November 2023).
Lilly built Zepbound as a separate brand to prevent insurance pushback on covering Mounjaro for off-label weight loss. The strategy worked — many insurers that won't approve Mounjaro for weight loss will approve Zepbound for the same patient with the same molecule, because Zepbound has the on-label indication.
If you're choosing between Mounjaro and Zepbound, you're really choosing which insurance pathway clears faster.
Mounjaro vs. Zepbound: side-by-side comparison
| Dimension | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide (same) |
| Doses available | 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg weekly | 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg weekly (same) |
| FDA approval | May 2022 | November 2023 |
| FDA indication | Type 2 diabetes | Chronic weight management |
| Maker | Eli Lilly | Eli Lilly (same) |
| Eligibility | Type 2 diabetes diagnosis | BMI ≥30, or ≥27 + comorbidity |
| Insurance coverage | Broad for diabetes | Variable for obesity (PA required) |
| LillyDirect vials | Not available | Available — $399–$549/mo cash pay |
| Cardiovascular evidence | SURPASS-CVOT in progress | SURMOUNT-MMO in progress |
| Side effect profile | Identical to Zepbound | Identical to Mounjaro |
| Compounded availability | Limited (off shortage list 2024) | Limited (off shortage list 2024) |
Mounjaro vs. Zepbound is a labeling exercise. The molecule is identical. The decision is which indication unlocks your insurance.
Cost comparison: Mounjaro vs. Zepbound in 2026
Real 2026 prices from active programs across savings cards, manufacturer cash-pay channels, retail pharmacies, and compounded alternatives.
| Cost path | Mounjaro | Zepbound |
|---|---|---|
| Savings card | $25/mo (diabetes patients) | $25/fill (eligible) |
| Cash through manufacturer | Standard Lilly cash (~$1,069) | LillyDirect vials $399–$549 |
| Retail cash price | $1,069/mo | $1,059/mo |
| Compounded tirzepatide | $249–$499/mo | $249–$499/mo (same molecule) |
When to choose Mounjaro vs. Zepbound
Choose Mounjaro if:
- ✓You have a Type 2 diabetes diagnosis — Mounjaro is the on-label choice
- ✓Your insurance covers Mounjaro for diabetes but not Zepbound for obesity
- ✓You're already on Mounjaro for diabetes and weight loss is a secondary benefit
- ✓You want Eli Lilly's branded diabetes savings card workflow
Choose Zepbound if:
- ✓You don't have diabetes but meet BMI criteria (≥30 or ≥27 + comorbidity)
- ✓Your insurance covers Zepbound for obesity but not Mounjaro off-label
- ✓You're cash-pay and want the LillyDirect single-dose vials at $399 (only available for Zepbound)
- ✓You want the on-label weight-management product for the cleanest PA path
Clinical evidence behind Mounjaro vs. Zepbound
SURPASS-2 (NEJM 2021): Mounjaro / tirzepatide produced superior A1C reduction vs. semaglutide in Type 2 diabetes — the largest head-to-head GLP-1 trial. SURMOUNT-1 (NEJM 2022): Zepbound / tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks in non-diabetic obesity patients. The molecule is the same; the trial programs branched per indication.
Top providers that prescribe Mounjaro or Zepbound
Providers we've verified for clinically appropriate Mounjaro or Zepbound pathways. Pricing and availability vary by state and insurance.
Ro Body
Major branded-Rx telehealth with a dedicated GLP-1 weight-loss program.
- ✓ Branded Wegovy / Zepbound when available
- ✓ Insurance coordination support
- ✓ Established national brand
- − Higher monthly cost
- − Intake and shipping slower than lean competitors
- − Not all medications in stock in all states
Sesame Care
A la carte telehealth where you pay per visit and get real GLP-1 prescriptions at list pricing.
- ✓ No subscription or recurring fee
- ✓ Pay once for the consult
- ✓ Use your own pharmacy + GoodRx
- − Medication cost is separate
- − No built-in coaching or support
- − Availability varies by state
Found
Weight-loss program that coordinates branded and compounded GLP-1 based on what your insurance covers.
- ✓ Handles prior authorizations
- ✓ Branded or compounded based on coverage
- ✓ Integrated coaching
- − Cost higher than cash-only peers
- − PA process can take weeks
- − Program requires 3-month commitment
Mounjaro vs. Zepbound: frequently asked
Are Mounjaro and Zepbound the same drug?
Same active ingredient — tirzepatide — from the same manufacturer (Eli Lilly), at the same dose ranges. The only difference is the FDA-approved label: Mounjaro for Type 2 diabetes, Zepbound for chronic weight management.
Why do both Mounjaro and Zepbound exist if they're the same drug?
Insurance and regulatory strategy. Lilly created Zepbound as a separate brand specifically for the obesity indication so that insurers wouldn't have to cover off-label Mounjaro for weight loss. This makes prior authorization for Zepbound for weight management cleaner than off-label Mounjaro for the same purpose.
Can I take Mounjaro for weight loss?
Off-label, yes — but insurance coverage is inconsistent and PA denials are common. For on-label weight loss, Zepbound is the right product.
Will my insurance cover Zepbound if I have diabetes?
Sometimes. Coverage of Zepbound requires the obesity indication. If you have diabetes only, Mounjaro is the on-label choice. If you have both diabetes AND BMI ≥30, your clinician picks based on which pathway clears.
Is one of them more effective than the other?
Same molecule at the same doses — efficacy is identical when matched dose-for-dose. The clinical trial programs (SURPASS for Mounjaro, SURMOUNT for Zepbound) targeted different patient populations, so the headline numbers differ, but the drug action is the same.
Are the side effects the same?
Yes — identical molecule, identical side effect profile. Nausea, constipation, GI distress concentrated in the first 8 weeks and at each dose increase.
What's LillyDirect and why does it only sell Zepbound?
LillyDirect is Eli Lilly's direct-to-patient cash pharmacy, launched in 2024. It sells single-dose Zepbound vials at $399–$549/month for uninsured patients. Mounjaro isn't available through LillyDirect — that channel is specifically for the weight-management product.
Should I switch from Mounjaro to Zepbound?
Only if your insurance situation changed (e.g., you developed BMI eligibility for the obesity indication and Zepbound now covers better than off-label Mounjaro). The drug itself is identical.